The UK government faces possible legal action after introducing changes that allow ministers to overturn decisions made by the National Institute for Health and Care Excellence (NICE) on which medicines the NHS should fund. Critics warn this adjustment, linked to a recent UK-US drug pricing agreement, undermines NICE's independence and risks increasing costs for NHS treatments.
NICE’s role has traditionally been independent, assessing clinical and cost effectiveness to help determine whether new medicines should be made available on the NHS in England and Wales. The recent statutory instrument, a form of secondary legislation, grants the health secretary the power to bypass these assessments.
This development forms part of a wider agreement announced last December between the UK government and the US administration. It aims to facilitate faster access to innovative drugs and maintain tariff-free UK drug exports to the US for three years. However, concerns have emerged about the potential consequences for NHS spending and the transparency of the deal's long-term impact.
Campaign groups Global Justice Now and Just Treatment have warned the Department of Health and Social Care (DHSC) that they may take the government to court, seeking a judicial review of the lawfulness of the new powers. They argue that bypassing NICE’s expert evaluations could lead to less effective oversight of drug pricing and limit parliamentary scrutiny.
Andrew Lansley, a former health secretary, has also criticised the change as conflicting with the Health and Social Care Act 2012, suggesting the government has overstepped legal boundaries. Members of Parliament from various parties have expressed unease about the lack of debate and disclosure related to the agreement, with no comprehensive impact assessment publicly available to date.
The DHSC maintains that NICE will continue to function independently, providing guidance free from political interference while balancing clinical benefits against cost considerations. A department spokesperson stated that the provisions ensure innovative medicines can reach patients more efficiently, highlighting the recent approval of a brain cancer drug for young patients as an example of progress.
Despite these assurances, critics point to the risks posed by ministerial override powers, which could pressure NICE to approve higher-priced drugs or treatments that do not meet established cost-effectiveness thresholds. For NHS patients and taxpayers, this could mean increased financial strain on the health service.
For the public, the key issues to watch include how the new powers are used in practice, whether they affect the availability and affordability of medicines, and if the government provides clear, transparent information about the ongoing costs and benefits of the UK-US pharmaceutical deal.
As this dispute unfolds, the legal and policy implications for NHS drug procurement remain significant. The challenge to NICE’s independence could reshape how treatment decisions are made, potentially affecting millions of patients who rely on NHS-funded medicines and the overall sustainability of healthcare budgets.
At present, the situation remains under close scrutiny, with possible court proceedings pending and Parliament yet to fully examine the ramifications of the changes. Patients and healthcare observers are advised to follow updates from official sources as further clarity emerges on how these new regulatory powers will be applied.